Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 17/20 | 0.74 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ingliforib SCHEMBL7239034 | 1.00 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| Ingliforib SCHEMBL13483321 | 1.00 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| Ingliforib SCHEMBL8739351 | 1.00 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| Ingliforib SCHEMBL6705938 | 1.00 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| Ingliforib SCHEMBL29388624 | 1.00 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| SCHEMBL7244130 | 0.95 | PYGL (0.74) | PYGLCYP51A1EGFR | |
| SCHEMBL13095871 | 0.94 | PYGL (0.68) | PYGLCYP51A1EGFR | |
| SCHEMBL14140946 | 0.94 | PYGL (0.68) | PYGLCYP51A1EGFR | |
| SCHEMBL15095241 | 0.94 | PYGL (0.68) | PYGLCYP51A1EGFR | |
| SCHEMBL6742819 | 0.90 | PYGL (0.78) | PYGLCYP51A1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| US-20110277339-A1 | METHOD FOR MAKING HOMOGENEOUS SPRAY-DRIED SOLID AMORPHOUS DRUG DISPERSIONS UTILIZING MODIFIED SPRAY-DRYING APPARATUS | LONZA BEND INC. | 2011-11-17 | — | — | US | claimed |
| US-20110182947-A1 | HYDROGEL-DRIVEN DRUG DOSAGE FORM | BEND RESEARCH, INC. | 2011-07-28 | — | — | US | claimed |
| EP-2275091-A1 | Pharmaceutical compositions comprising adsorbates of an amorphous drug | Pfizer Products Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | claimed |
| US-6297269-B1 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | PFIZER INC. | 2001-10-02 | — | — | US | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| US-12186317-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2025-01-07 | — | — | US | disclosed |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | disclosed |
| US-20220354848-A9 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2022-11-10 | — | — | US | disclosed |
| EP-3526199-B1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S R L (IT) | 2022-04-13 | — | — | EP | disclosed |
| US-20040152758-A1 | N-(indole-2-carbonyl)-b-alaninamide crystal forms | PFIZER INC. | 2004-08-05 | — | — | US | disclosed |
| US-6683106-B2 | REDUCED SIDE EFFECTS; EFFICACY | PFIZER INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030195243-A1 | N-(indole-2-carbonyl)-b-alaninamide crystal forms | PFIZER INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195243-A1 | N-(indole-2-carbonyl)-b-alaninamide crystal forms | PYGL, PYGB, PYGM | PYGL 1/4885CYP51A1 1806/4885EGFR 4056/4885 |
| US-20220354848-A9 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | PYGL 483/4885CYP51A1 832/4885EGFR 3729/4885 |
| US-12186317-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | ACMSD, GLS, ALDH7A1 | PYGL 483/4885CYP51A1 832/4885EGFR 3729/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PYGL 1869/4885CYP51A1 876/4885EGFR 1068/4885 |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | PYGL 483/4885CYP51A1 832/4885EGFR 3729/4885 |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | PYGL 1/4885CYP51A1 688/4885EGFR 4764/4885 |
| US-20040152758-A1 | N-(indole-2-carbonyl)-b-alaninamide crystal forms | PYGL, PYGB, PYGM | PYGL 1/4885CYP51A1 1806/4885EGFR 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.